Amazon intensifies push into Australian pharmacy with trademark application

Smh | June 01, 2020

Retail giant Amazon has intensified its push into Australia's highly competitive pharmaceuticals sector, brushing off industry opposition with a fresh trademark application for a range of private-label over-the-counter medications. Amazon filed the application for the 'BasicCare' trademark on Friday and refers to Amazon-branded medication which shoppers can buy directly from the e-commerce giant. The move comes as Amazon faces a fight with the Pharmacy Guild of Australia over a previous application for the trademark 'Amazon Pharmacy', which it filed in January this year.

Spotlight

Jose-Carlos Gutierrez-Ramos, Ph.D., Senior Vice President and Head of BioTherapeutics Research & Development at Pfizer, discusses the R&D ecosystem of the future.

Spotlight

Jose-Carlos Gutierrez-Ramos, Ph.D., Senior Vice President and Head of BioTherapeutics Research & Development at Pfizer, discusses the R&D ecosystem of the future.

Related News

PHARMA TECH

PathAI Announces Strategic Partnership with Roche to Enable Development and Distribution of Digital Pathology Diagnostics

Roche | October 15, 2021

PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Roche, a global pioneer in pharmaceuticals and diagnostics, announced a strategic partnership to develop and distribute PathAI's AI-powered technology through Roche's uPath enterprise software, enabling broad access to digital pathology diagnostics to support clinical research and companion diagnostic (CDx) programs globally. AI-powered pathology has the potential to inform biomarker development, better identify and treat patients, and enable personalized medicine. However, the digital pathology industry is largely fragmented across various software, hardware and algorithm providers, which has prevented effective implementation of AI platforms in labs. The collaboration between PathAI and Roche now provides a comprehensive menu of AI-powered digital pathology solutions in diagnostics. "This collaboration brings together all of the components required to deliver and commercialize a differentiated AI-based digital pathology medical device including assay, scanner, image management system, and image analysis algorithms. We believe this collaboration will unlock the potential for digital pathology in the CDx setting, offering a differentiated service to biopharma sponsors and ultimately new opportunities to improve patient outcomes," - Dr. Andy Beck, CEO of PathAI. The collaboration will initially involve distribution of PathAI-developed research-use-only (RUO) algorithms through NAVIFY Digital Pathology, the cloud version of Roche's uPath enterprise software, focusing on immuno-oncology in multiple cancer types. The collaboration will also support biopharmaceutical partners with an end-to-end solution for CDx development, leveraging Roche's diagnostic assays and pathology lab solutions with new and expanded innovative imaging tools from PathAI, in addition to the AI tools already provided by Roche. About PathAI PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognized as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Read More

BUSINESS INSIGHTS

Iterative Scopes Acquires Clinical Research Strategy Group and Precision Research

Iterative Scopes | April 29, 2022

On April 28, Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced that it acquired Clinical Research Strategy Group, LLC, and Precision Research. These two clinical trial optimization companies focus on streamlining and speeding the drug development process for inflammatory bowel disease (IBD). Through this acquisition, Iterative Scopes’ ties to the IBD clinical research community are deepened, and its knowledge of the end-to-end research process keeping in mind the provider viewpoints and pain points, has been strengthened. It will improve patient outcomes by providing improved treatment options. Chris Fourment, MD, the President, and CEO of both the companies, is a leading expert on clinical trials in IBD. He has joined Iterative Scopes as SVP of Clinical Strategy. Founded in 2017, Iterative Scopes was a spin-out of the Massachusetts Institute of Technology (MIT) by Dr. Ng, a physician-entrepreneur who developed the company’s foundational concepts while studying at MIT and Harvard. In December 2021, the company and its investors closed a $150 million Series B funding. It attracted a roster of A-list venture capitalists, big pharma companies, and leaders in healthcare. “I am excited to join Iterative Scopes to help the organization further harness machine learning and computer vision to aid physicians as they work to improve clinical outcomes for IBD patients earlier and with greater success. The current clinical trial process for IBD drug development has patient recruitment and clinical team workflow challenges. Iterative Scopes is employing cutting-edge computational algorithms and support services that have the potential to resolve these challenges.” Dr. Fourment Iterative Scopes founder and CEO Dr. Jonathan Ng said, “With the addition of CRSG and Precision, Iterative Scopes has the opportunity to work more closely with different types of clinical trial sites and providers and to gain sophisticated insights about their needs and pain points, with the goal of refining our ground-breaking AI Recruitment service. Community sites face different challenges and opportunities than other types of providers, and these acquisitions help us create an intimate, holistic and fulsome knowledge of all stakeholders involved in the research process. While I have known Chris for some time now, we are thrilled to finally have him aboard our team, bringing his globally renowned expertise in IBD research to Iterative Scopes."

Read More

PHARMA TECH

Feds rebuff Pfizer's pleas to speed up supplies of COVID-19 vaccine raw materials

Pfizer | December 21, 2020

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in its unique agreement with the U.S. government in the main portion of one year from now—however just if Trump organization authorities request that providers of crude materials rapidly satisfy the organization's requests. Furthermore, CEO Albert Bourla, Ph.D., is approaching the public authority to utilize the Defense Production Act to do precisely that. The Trump organization hasn't done as such yet on the grounds that they've zeroed in on giving those materials to antibody producers that took government R&D subsidizing, as Moderna, as indicated by anonymous sources who addressed The New York Times. A representative for Pfizer declined to remark, refering to the privacy of conversations with the U.S. government. Yet, Bourla said during a CNBC meet that the organization is in exchanges to sell an extra 100 million dosages of Pfizer's COVID-19 immunization to the U.S. government. "We can give a ton of that in the second from last quarter. The U.S. government needs it in the subsequent quarter," Bourla said in the Monday meet. "We are working cooperatively to attempt to discover an answer and have the option to apportion those 100 million [doses] in the subsequent quarter if conceivable, or a ton of them." Pfizer mentioned almost immediately that the public authority grant it "supported status" with providers of crude materials, however authorities were anxious about the possibility that that would harm contending immunization programs that took government R&D cash, as per the Times report. Among those organizations is Moderna, which is required to win crisis use approval from the FDA for its mRNA immunization this week—and last Friday, inked an arrangement to add 100 million additional portions to its underlying U.S. request.

Read More